Related Experiment Video
Updated: Mar 3, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
Targets for Heart Failure With Preserved Ejection Fraction
1Alfred Hospital and Baker Heart & Diabetes Institute, Melbourne, Australia.
Abstract:
Heart failure (HF) with preserved ejection fraction (HFPEF) is responsible for half of all HF cases and will be the most common form of HF within the next 5 years. Previous studies of pharmacological agents in HFPEF have proved neutral or negative, in part due to phenotypic heterogeneity and complex underlying mechanisms. This review summarizes the key molecular and cellular pathways characterized in HFPEF as well as current and future therapies that target these mechanisms.
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure II: Pathophysiology
Heart Failure VI: Adjunct Therapies
Pathophysiology of Heart Failure

